These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8898828)

  • 1. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial.
    Tilley BC; Marler J; Geller NL; Lu M; Legler J; Brott T; Lyden P; Grotta J
    Stroke; 1996 Nov; 27(11):2136-42. PubMed ID: 8898828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I.
    Hacke W; Bluhmki E; Steiner T; Tatlisumak T; Mahagne MH; Sacchetti ML; Meier D
    Stroke; 1998 Oct; 29(10):2073-5. PubMed ID: 9756584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
    Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
    N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial.
    Stroke; 1997 Nov; 28(11):2119-25. PubMed ID: 9368551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
    National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
    Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study.
    Steiner T; Bluhmki E; Kaste M; Toni D; Trouillas P; von Kummer R; Hacke W
    Cerebrovasc Dis; 1998; 8(4):198-203. PubMed ID: 9684058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue plasminogen activator for acute ischemic stroke.
    National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
    N Engl J Med; 1995 Dec; 333(24):1581-7. PubMed ID: 7477192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.
    Stroke; 1997 Nov; 28(11):2109-18. PubMed ID: 9368550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
    Stroke; 1997 Aug; 28(8):1530-40. PubMed ID: 9259745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
    Hertzberg V; Ingall T; O'Fallon W; Asplund K; Goldfrank L; Louis T; Christianson T
    Clin Trials; 2008; 5(4):308-15. PubMed ID: 18697845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
    Hacke W; Kaste M; Fieschi C; Toni D; Lesaffre E; von Kummer R; Boysen G; Bluhmki E; Höxter G; Mahagne MH
    JAMA; 1995 Oct; 274(13):1017-25. PubMed ID: 7563451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated-measures analysis of the National Institute of Neurological Disorders and Stroke rt-PA stroke trial.
    Feng W; Vasquez G; Suri MF; Lakshminarayan K; Qureshi AI
    J Stroke Cerebrovasc Dis; 2011; 20(3):241-6. PubMed ID: 20621509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
    Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
    Ingall TJ; O'Fallon WM; Asplund K; Goldfrank LR; Hertzberg VS; Louis TA; Christianson TJ
    Stroke; 2004 Oct; 35(10):2418-24. PubMed ID: 15345796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
    Kwiatkowski T; Libman R; Tilley BC; Lewandowski C; Grotta JC; Lyden P; Levine SR; Brott T;
    Ann Emerg Med; 2005 Apr; 45(4):377-84. PubMed ID: 15795715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
    Tilley BC; Lyden PD; Brott TG; Lu M; Levine SR; Welch KM
    Arch Neurol; 1997 Dec; 54(12):1466-74. PubMed ID: 9400355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.
    Adeoye O; Knight WA; Khoury J; Schmit PA; Sucharew H; Broderick JP; Pancioli AM;
    J Stroke Cerebrovasc Dis; 2014; 23(5):e313-5. PubMed ID: 24534128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
    Patel SC; Levine SR; Tilley BC; Grotta JC; Lu M; Frankel M; Haley EC; Brott TG; Broderick JP; Horowitz S; Lyden PD; Lewandowski CA; Marler JR; Welch KM;
    JAMA; 2001 Dec; 286(22):2830-8. PubMed ID: 11735758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.